Marimed (MRMD) Cash & Equivalents (2011 - 2026)

Marimed (MRMD) has 16 years of Cash & Equivalents data on file, last reported at $7.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 10.22% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 10.22% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 22.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.9 million, down from $8.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MRMD reached as high as $33.5 million in Q1 2022 and fell as low as $6.1 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $12.1 million across 5 years, with a median of $9.8 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 171.68% in 2022 and fell as far as 67.2% in 2022.
• Year by year, Cash & Equivalents stood at $9.7 million in 2022, then soared by 50.41% to $14.6 million in 2023, then slumped by 50.28% to $7.3 million in 2024, then advanced by 22.0% to $8.9 million in 2025, then retreated by 10.66% to $7.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.9 million in Q1 2026, $8.9 million in Q4 2025, and $6.6 million in Q3 2025.